公开(公告)号：US20190160023A1

公开(公告)日：2019-05-30

申请号：US16092374

申请日：2017-04-11

申请人： GW Research Limited

发明人： Geoffrey GUY ,  Stephen WRIGHT ,  James BRODIE ,  Marie WOOLLEY-ROBERTS ,  Rafael MALDONADO ,  Daniela PAROLARO ,  Livio LUONGO ,  Joanna NEILL

IPC分类号： A61K31/05 ,  A61K36/185 ,  A61P25/18 ,  A61P25/28

摘要： The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.

公开(公告)号：US20230301936A1

公开(公告)日：2023-09-28

申请号：US18320906

申请日：2023-05-19

申请人： GW Research Limited

发明人： Geoffrey GUY ,  Stephen WRIGHT ,  Orrin DEVINSKY

IPC分类号： A61K31/05 ,  A61K31/195 ,  A61K31/20 ,  A61K31/27 ,  A61K31/352 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/496 ,  A61K31/53 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K31/165 ,  A61K31/19 ,  A61K31/197 ,  A61K31/35 ,  A61K31/36 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44 ,  A61K9/00 ,  A61K9/08 ,  A61K31/444 ,  A61K31/515 ,  A61K31/55

CPC分类号： A61K31/05 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/20 ,  A61K31/27 ,  A61K31/35 ,  A61K31/352 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/444 ,  A61K31/496 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44

摘要： The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

公开(公告)号：US20230032502A1

公开(公告)日：2023-02-02

申请号：US17705443

申请日：2022-03-28

申请人： GW Research Limited

发明人： Geoffrey GUY ,  Stephen WRIGHT ,  Alice MEAD ,  Orrin DEVINSKY

IPC分类号： A61K31/05 ,  A61K36/185 ,  A61K31/352

摘要： The present disclosure relates to the use of cannabidiol (CBD) for the treatment of of nocturnal snoring. In particular the CBD appears particularly effective in treating nocturnal snoring in children and young adults with epilepsy The disclosure further relates to the use of CBD in 5 combination with one or more anti-epileptic drugs (AEDs).

公开(公告)号：US20220387348A1

公开(公告)日：2022-12-08

申请号：US17744224

申请日：2022-05-13

申请人： GW Research Limited

发明人： Geoffrey GUY ,  Stephen WRIGHT ,  Orrin DEVINSKY

IPC分类号： A61K31/05 ,  A61K36/185 ,  A61P25/08

摘要： The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.

公开(公告)号：US20220378717A1

公开(公告)日：2022-12-01

申请号：US17816349

申请日：2022-07-29

申请人： GW Research Limited

发明人： Geoffrey GUY ,  Stephen WRIGHT ,  Orrin DEVINSKY

IPC分类号： A61K31/05 ,  A61K31/195 ,  A61K31/20 ,  A61K31/27 ,  A61K31/352 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/496 ,  A61K31/53 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K31/165 ,  A61K31/19 ,  A61K31/197 ,  A61K31/35 ,  A61K31/36 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44 ,  A61K9/00 ,  A61K9/08 ,  A61K31/444 ,  A61K31/515 ,  A61K31/55

摘要： The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

公开(公告)号：US20210401771A1

公开(公告)日：2021-12-30

申请号：US17472016

申请日：2021-09-10

申请人： GW Research Limited

发明人： Geoffrey GUY ,  Stephen WRIGHT ,  Orrin DEVINSKY

IPC分类号： A61K31/05 ,  A61K31/195 ,  A61K31/20 ,  A61K31/27 ,  A61K31/352 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/496 ,  A61K31/53 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K31/165 ,  A61K31/19 ,  A61K31/197 ,  A61K31/35 ,  A61K31/36 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44 ,  A61K9/00 ,  A61K9/08 ,  A61K31/444 ,  A61K31/515 ,  A61K31/55

摘要： The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

公开(公告)号：US20230248664A1

公开(公告)日：2023-08-10

申请号：US18186792

申请日：2023-03-20

申请人： GW Research Limited

发明人： Geoffrey GUY ,  Stephen WRIGHT ,  Orrin DEVINSKY

IPC分类号： A61K31/05 ,  A61K47/10 ,  A61K9/08 ,  A61K45/06 ,  A61K31/352

CPC分类号： A61K31/05 ,  A61K9/08 ,  A61K31/352 ,  A61K45/06 ,  A61K47/10

摘要： The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

公开(公告)号：US20220323375A1

公开(公告)日：2022-10-13

申请号：US17853367

申请日：2022-06-29

申请人： GW Research Limited

发明人： Geoffrey GUY ,  Stephen WRIGHT ,  Elizabeth THIELE

IPC分类号： A61K31/05 ,  A61K45/06 ,  A61K36/185 ,  A61K31/352 ,  A61K9/00

摘要： The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

公开(公告)号：US20220202738A1

公开(公告)日：2022-06-30

申请号：US17689607

申请日：2022-03-08

申请人： GW Research Limited

发明人： Geoffrey GUY ,  Stephen WRIGHT ,  Orrin DEVINSKY

IPC分类号： A61K31/05 ,  A61K31/195 ,  A61K31/20 ,  A61K31/27 ,  A61K31/352 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/496 ,  A61K31/53 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K31/165 ,  A61K31/19 ,  A61K31/197 ,  A61K31/35 ,  A61K31/36 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44 ,  A61K9/00 ,  A61K9/08 ,  A61K31/444 ,  A61K31/515 ,  A61K31/55

摘要： The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

公开(公告)号：US20210205262A1

公开(公告)日：2021-07-08

申请号：US17128458

申请日：2020-12-21

申请人： GW Research Limited

发明人： Geoffrey GUY ,  Stephen WRIGHT ,  James BRODIE ,  Marie WOOLLEY-ROBERTS ,  Rafael MALDONADO ,  Daniela PAROLARO ,  Livio LUONGO

IPC分类号： A61K31/352 ,  A61K45/06 ,  A61K31/05 ,  A61K36/185 ,  A61P43/00

摘要： The present invention relates to the use of cannabidiolic acid (CBDA) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders, such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). CBDA has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS and AS. The CBDA is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDA is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDA is synthetically produced.